Skip to main content
Premium Trial:

Request an Annual Quote

Bruker BioSciences Nets $16.9M in Public Stock Offering

This article has been updated from a previous version, which reported the value of the total public offering, rather than the value of Bruker BioSciences' net proceeds.
 
NEW YORK (GenomeWeb News) — Bruker BioSciences today gained $16.9 million in proceeds from a public offering of its common stock.
 
The company said it sold 2.53 million of its shares at $7.10 per share. An additional 9.4 million shares were sold by four stockholders. Bruker did not realize any of the net proceeds from the sale of stock by these shareholders.
 
Bruker plans to use the proceeds for corporate purposes, including repaying debt and for potential acquisitions.
 
Bruker said 1.6 million shares of this offering were sold after the underwriters exercised an over-allotment option.
 
Bear, Stearns & Co. and UBS Investment Bank are serving as joint bookrunning managers for the offering.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.